Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

reatening problems."

The sickle cell trial grew out of research by Dr. Linden, who is a leading expert on adenosine receptors, which are known to act as a natural brake on inflammation. While Dr. Linden had previously explored adenosine's role in protecting tissues from damage due to low blood flow in single tissues such as in heart disease, he was struck one day with the idea that it might also protect people with sickle cell disease, who suffer tissue damage from poor blood flow to most tissues.

Dr. Linden began testing his theory in mouse models about four years ago and found that adenosine-like compounds significantly reduced the damaging effects of the disease. He was aware of an existing FDA approved adenosine-like drug, Lexiscan that had already been approved for another use. "This was good news since it meant that Lexiscan was known to be safe in humans and could probably gain rapid approval if proven effective in clinical trials as a treatment for sickle cell disease," he said.

Dr. Linden joined forces with Dr. Nathan, who participated in the development of the only existing FDA-approved drug for sickle cell treatment, hydroxyurea, and another clinical collaborator, Dr. Field, to seek NIH funding for the Lexiscan trial. They launched the trial's first phase in 2010 using patient volunteers from Brigham and Women's Hospital in Boston and Washington University in St. Louis.

In the trial, Dr. Nathan, Dr. Field and other clinicians collected blood from patients and sent it to Dr. Linden in La Jolla for analysis of white blood cell inflammation. Gene Lin, Ph.D., a scientist in Linden's lab, has been a significant contributor to the analysis effort. The same protocol will be used in the trial's second phase.

Lexiscan is approved as a pharmacologic stress agent used for myocardial perfusion imaging (MPI), a procedure that measures coronary blood flow to help in the diagnosis of heart disease. Lexiscan is u
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... Imaging is the first handbook of its ... visualization of microcirculation. Clearly structured throughout, this ... researcher relying on microcirculation imaging. , Author Professor ... Ireland, Galway, explores everything from basic research to ...
... not changed since the 2010-11 pilot run of the Yuma ... of Arizona-led binational team of researchers. The 15,000-acre cinega, ... to several endangered species and is a major stopover for ... lies within Mexico,s Biosphere Reserve for the Upper Gulf of ...
... Older women with insufficient levels of Vitamin D gained more weight ... new study funded by the National Institutes of Health and published ... study of more than 4,600 women ages 65 and older found ... D in their blood gained about two pounds more than those ...
Cached Biology News:Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 2Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 3Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 4Low vitamin D levels linked to weight gain in some older women 2
(Date:5/25/2015)... , May 26, 2015  PureTech, a science-driven ... health challenges in disruptive ways, announced today that Dame ... and former CEO of Pearson, has been appointed to ... Independent Director and that current Board member Joi ... Board Chairman. Dr. Ben Shapiro , PureTech,s outgoing ...
(Date:5/25/2015)... Phenome Networks, a software-as-a-service plant breeding ... beginning May 31st, of its next-generation Phenome One software. ... Phenome Networks’ lead in the plant breeding market, through ... breeding workflow based on years of experience with plant ... and more. The new version of Phenome One, Phenome ...
(Date:5/22/2015)... MA (PRWEB) May 22, 2015 ... the U.S. Department of Agriculture (USDA), Grain Inspection, ... five year contract to Charm Sciences to monitor ... Quantitative Test (water-based) and ROSA FAST Aflatoxin Quantitative ... Aflatoxin Quantitative Test uses Water Extraction Technology ...
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
Breaking Biology Technology:PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8
... 6 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix for the drug delivery,endocrinology, oncology, and ... and nine months ended September 30, 2008., ... and I am,pleased with the initiation of our ...
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... Company at the Rodman & Renshaw 10th Annual,Healthcare Conference ... The,event will be held at the New York Palace ... webcast of the presentation will be available at:, http://www.wsw.com/webcast/rrshq14/oncy ...
... * Submitted NDA with FDA for NGX-4010 for management of pain associated ... ... Day 120 questions regarding MAA under ... Calif., Nov. 6 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
... For the ultimate in utility and flexibility ... meet the needs of the researcher. They ... dimensions or as sheet material that can ... These isolators are autoclavable and non-cytotoxic and ...
Biology Products: